We are analyzing https://link.springer.com/article/10.1007/s10549-013-2560-8.

Title:
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry | Breast Cancer Research and Treatment
Description:
The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of this study was to evaluate the routine use and value of Ki-67 as a prognostic marker, and to analyze the associations between Ki-67 and common histopathological parameters in the routine clinical setting. Data from the clinical cancer registry Regensburg (Bavaria, Germany) were analyzed. Within the total data pool of 4,692 female patients, who had been diagnosed between 2005 and 2011, in 3,658 cases Ki-67 was routinely determined. Thus, a total of 3,658 patients with invasive breast cancer were included in the present study and used for statistical analysis. Ki-67 expression was associated with the common histopathological parameters. The strongest correlation was found between grading and Ki-67 (P < 0.001). In terms of survival analyses, Ki-67 was categorized into five categories (reference category Ki-67 ≤15 %) due to a nonlinear relationship to overall survival (OS). In multivariable analysis, Ki-67 was an independent prognostic parameter both for disease-free survival (DFS) (Ki-67 > 45 %, HR = 1.96, P = 0.001) as well as for OS (Ki-67: 26–35 %, HR = 1.71, P = 0.017; Ki-67: 36–45 %, HR = 2.05, P = 0.011; Ki-67 > 45 %, HR = 2.06, P = 0.002) independent of common clinical and histopathological factors. The 5-year DFS (OS) rate was 86.7 % (89.3 %) in patients with a Ki-67 value ≤15 % compared to 75.8 % (82.8 %) in patients with a Ki-67 value >45 %. Based on the data from a large cohort of a clinical cancer registry, it was demonstrated that Ki-67 is frequently determined in routine clinical work. Ki-67 expression is associated with common histopathological parameters, but is an additional independent prognostic parameter for DFS and OS in breast cancer patients. Future work should focus on standardization of Ki-67 assessment and specification of its role in treatment decisions.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

cancer, breast, patients, article, google, scholar, pubmed, prognostic, clinical, cas, tumors, analysis, data, tumor, parameters, survival, proliferation, routine, dfs, studies, histopathological, values, study, table, status, res, treatment, registry, regensburg, analyses, early, cell, index, higher, primary, quartiles, size, marker, number, grading, parameter, pathology, full, expression, found, independent, prognosis, markers, quality, chemotherapy,

Topics {✒️}

anti-pcna/cyclin monoclonal antibodies high-pretreatment ki-67-labeling index multivariable cox-regression model triple-negative biologic classes main cox-regression analysis multivariable cox-regression analysis article download pdf triple-negative breast cancer prognostic markers e-cadherin node-negative breast cancer lymphoma-descended cell line year disease-free survival endocrine-responsive breast cancer german robert-koch institute early-stage breast cancer kaplan–meier survival curves retrospective population-based analysis large population-based cohort disease-free survival standard clinico-pathological variables high-ki-67-labeling index full size table robust biomarkers measured low-ki-67-labeling index node-negative disease regional registry offices privacy choices/manage cookies human breast cancer external quality assurance her2/neu negative tumors human breast tumours human nuclear antigen quality assurance conferences ensure quality assurance ki-67-positive nuclear immunostaining her2/neu positive tumors cancer registry area node-negative stage full data sets clinical cancer registry primary breast cancer invasive breast cancer breast cancer tissue early breast cancer breast cancer-related dotted lines represent loehberg cr tumour shrinkage breast cancer subtyping van de rijn

Questions {❓}

Colozza M, Azambuja E, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
         description:The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of this study was to evaluate the routine use and value of Ki-67 as a prognostic marker, and to analyze the associations between Ki-67 and common histopathological parameters in the routine clinical setting. Data from the clinical cancer registry Regensburg (Bavaria, Germany) were analyzed. Within the total data pool of 4,692 female patients, who had been diagnosed between 2005 and 2011, in 3,658 cases Ki-67 was routinely determined. Thus, a total of 3,658 patients with invasive breast cancer were included in the present study and used for statistical analysis. Ki-67 expression was associated with the common histopathological parameters. The strongest correlation was found between grading and Ki-67 (P < 0.001). In terms of survival analyses, Ki-67 was categorized into five categories (reference category Ki-67 ≤15 %) due to a nonlinear relationship to overall survival (OS). In multivariable analysis, Ki-67 was an independent prognostic parameter both for disease-free survival (DFS) (Ki-67 > 45 %, HR = 1.96, P = 0.001) as well as for OS (Ki-67: 26–35 %, HR = 1.71, P = 0.017; Ki-67: 36–45 %, HR = 2.05, P = 0.011; Ki-67 > 45 %, HR = 2.06, P = 0.002) independent of common clinical and histopathological factors. The 5-year DFS (OS) rate was 86.7 % (89.3 %) in patients with a Ki-67 value ≤15 % compared to 75.8 % (82.8 %) in patients with a Ki-67 value >45 %. Based on the data from a large cohort of a clinical cancer registry, it was demonstrated that Ki-67 is frequently determined in routine clinical work. Ki-67 expression is associated with common histopathological parameters, but is an additional independent prognostic parameter for DFS and OS in breast cancer patients. Future work should focus on standardization of Ki-67 assessment and specification of its role in treatment decisions.
         datePublished:2013-05-16T00:00:00Z
         dateModified:2013-05-16T00:00:00Z
         pageStart:539
         pageEnd:552
         sameAs:https://doi.org/10.1007/s10549-013-2560-8
         keywords:
            Ki-67
            Primary breast cancer
            Cancer Registry
            Prognostic factor
            Disease-free survival
            Overall survival
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig4_HTML.gif
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:139
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:E. C. Inwald
               affiliation:
                     name:University of Regensburg
                     address:
                        name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:M. Klinkhammer-Schalke
               affiliation:
                     name:University of Regensburg
                     address:
                        name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Hofstädter
               affiliation:
                     name:University of Regensburg
                     address:
                        name:Institute of Pathology, University of Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:F. Zeman
               affiliation:
                     name:University Hospital Regensburg
                     address:
                        name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Koller
               affiliation:
                     name:University Hospital Regensburg
                     address:
                        name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Gerstenhauer
               affiliation:
                     name:University of Regensburg
                     address:
                        name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:O. Ortmann
               affiliation:
                     name:University of Regensburg
                     address:
                        name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
      description:The proliferation marker Ki-67 is one of the most controversially discussed parameters for treatment decisions in breast cancer patients. The purpose of this study was to evaluate the routine use and value of Ki-67 as a prognostic marker, and to analyze the associations between Ki-67 and common histopathological parameters in the routine clinical setting. Data from the clinical cancer registry Regensburg (Bavaria, Germany) were analyzed. Within the total data pool of 4,692 female patients, who had been diagnosed between 2005 and 2011, in 3,658 cases Ki-67 was routinely determined. Thus, a total of 3,658 patients with invasive breast cancer were included in the present study and used for statistical analysis. Ki-67 expression was associated with the common histopathological parameters. The strongest correlation was found between grading and Ki-67 (P < 0.001). In terms of survival analyses, Ki-67 was categorized into five categories (reference category Ki-67 ≤15 %) due to a nonlinear relationship to overall survival (OS). In multivariable analysis, Ki-67 was an independent prognostic parameter both for disease-free survival (DFS) (Ki-67 > 45 %, HR = 1.96, P = 0.001) as well as for OS (Ki-67: 26–35 %, HR = 1.71, P = 0.017; Ki-67: 36–45 %, HR = 2.05, P = 0.011; Ki-67 > 45 %, HR = 2.06, P = 0.002) independent of common clinical and histopathological factors. The 5-year DFS (OS) rate was 86.7 % (89.3 %) in patients with a Ki-67 value ≤15 % compared to 75.8 % (82.8 %) in patients with a Ki-67 value >45 %. Based on the data from a large cohort of a clinical cancer registry, it was demonstrated that Ki-67 is frequently determined in routine clinical work. Ki-67 expression is associated with common histopathological parameters, but is an additional independent prognostic parameter for DFS and OS in breast cancer patients. Future work should focus on standardization of Ki-67 assessment and specification of its role in treatment decisions.
      datePublished:2013-05-16T00:00:00Z
      dateModified:2013-05-16T00:00:00Z
      pageStart:539
      pageEnd:552
      sameAs:https://doi.org/10.1007/s10549-013-2560-8
      keywords:
         Ki-67
         Primary breast cancer
         Cancer Registry
         Prognostic factor
         Disease-free survival
         Overall survival
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10549-013-2560-8/MediaObjects/10549_2013_2560_Fig4_HTML.gif
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:139
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:E. C. Inwald
            affiliation:
                  name:University of Regensburg
                  address:
                     name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:M. Klinkhammer-Schalke
            affiliation:
                  name:University of Regensburg
                  address:
                     name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Hofstädter
            affiliation:
                  name:University of Regensburg
                  address:
                     name:Institute of Pathology, University of Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:F. Zeman
            affiliation:
                  name:University Hospital Regensburg
                  address:
                     name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Koller
            affiliation:
                  name:University Hospital Regensburg
                  address:
                     name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Gerstenhauer
            affiliation:
                  name:University of Regensburg
                  address:
                     name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:O. Ortmann
            affiliation:
                  name:University of Regensburg
                  address:
                     name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:139
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Regensburg
      address:
         name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University of Regensburg
      address:
         name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University of Regensburg
      address:
         name:Institute of Pathology, University of Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University Hospital Regensburg
      address:
         name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University Hospital Regensburg
      address:
         name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University of Regensburg
      address:
         name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
         type:PostalAddress
      name:University of Regensburg
      address:
         name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:E. C. Inwald
      affiliation:
            name:University of Regensburg
            address:
               name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:M. Klinkhammer-Schalke
      affiliation:
            name:University of Regensburg
            address:
               name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      name:F. Hofstädter
      affiliation:
            name:University of Regensburg
            address:
               name:Institute of Pathology, University of Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      name:F. Zeman
      affiliation:
            name:University Hospital Regensburg
            address:
               name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      name:M. Koller
      affiliation:
            name:University Hospital Regensburg
            address:
               name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      name:M. Gerstenhauer
      affiliation:
            name:University of Regensburg
            address:
               name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
      name:O. Ortmann
      affiliation:
            name:University of Regensburg
            address:
               name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany
      name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
      name:Institute of Pathology, University of Regensburg, Regensburg, Germany
      name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
      name:Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
      name:Tumor Center Regensburg e.V., University of Regensburg, Regensburg, Germany
      name:Department of Gynecology and Obstetrics, University of Regensburg, Regensburg, Germany

External Links {🔗}(216)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Hammer.js
Prism.js

CDN Services {📦}

Crossref

5.09s.

LINK . SPRINGER . COM {}